Rigel Pharmaceuticals reports Q2 EPS $3.91, consensus $1.40

Reports Q2 revenue $101.7M, consensus $72.58M. Total revenue and net income are inclusive of $40M in non-cash contract revenue related to Rigel’s agreement with Lilly. “Our strategic and disciplined approach to building our business has m generated another strong quarter for the company. In the Q2 we grew net product sales by 76% year-over-year, generated $59.6in net income and increased our cash balance to $108.4M. This strong performance has enabled us to raise our 2025 financial guidance,” said Raul Rodriguez, Rigel’s president and CEO. “We’re also excited by the continued advancement of our hematology and oncology development pipeline. In July, we completed enrollment in the dose escalation part of our ongoing Phase 1b study evaluating R289 in patients with relapsed or refractory lower-risk MDS. Later this year, we plan to share updated data from that study and initiate the dose expansion part of the study.”